The following event and verbatim narrative were received from Roche.
AER 1512248 is a non-interventional program case, received on 22/Jan/2007, from a physician via other health 
care professional and company representative and concerns a 11 years old female patient (patient number- (b) (6) )
who had blood is sputum, allergy to Neulasta and experienced foreign body sensation in throat while participating in
(b) (6)
(b) (6)
Medical history included surgery, radiation therapy and allergy to vancomycin. Concomitant medications included 
ondansetron, ranitidine hydrochloride, diphenhydramine hydrochloride, oxycodone hydrochloride, polyethylene 
glycol, docusate sodium, paracetamol, morphine sulphate, celecoxib, duloxetine hydrochloride, gabapentin, 
dexamethasone, sulfamethoxazole/trimethoprim. Past drugs included radiation vancomycin hydrochloride, 
gemcitabine hydrochloride, methotrexate and docetaxel. No concurrent conditions were reported.
On an unspecified date, the patient started therapy pegfilgrastim (therapy details not provided) and doxorubicin 
hydrochloride (therapy details not provided) for an unknown indication. On 21/Nov/2006, patient started therapy with
intravenous bevacizumab infusion 190mg, once every 2 weeks for malignant neoplasm of long bones of lower limb 
(stage III B). On same day, her blood pressure (BP) was 117/60, pulse 89 and temperature 98.7 F. It was reported 
that when the patient came last week for bevacizumab, she was unable to get this due to doxorubicin hydrochloride
reaction and complained of feeling like something is in her throat (captured as foreign sensation in throat) and 
blood in sputum. It was reported that she had allergy to pegfilgrastim. on 05/Dec/2006, her lab results showed white
blood cell count (WBC) was 7.7, hemoglobin (HGB) 8.9, platelet (PLT) 294, absolute neutrophil count (ANC) 4.7 
and she received bevacizumab 190 mg. On 19/Dec/2006, her lab results showed WBC was 6.8, HGB 9, PLT 357 
and ANC 3.6. Her BP was 109/63, temperature 97.8 F and heart rate (HR) 104. She received bevacizumab 190 
mg. On 02/Jan/2007, her lab results showed WBC was 7.7, HGB 8.9, PLT 294 and ANC 4.7. Her BP was 98/60 
sitting, TqR 91 b/min and temperature was 98 F. She received bevacizumab 190 mg.
At the time of report, outcome of blood is sputum, allergy to Neulasta and foreign body sensation in throat were not 
reported and it was not known whether therapy with bevacizumab, pegfilgrastim and doxorubicin hydrochloride was 
ongoing or not.
The reporter assessed the causality for allergy to Neulasta as related to pegfilgrastim and did not provide the 
causality for blood is sputum and foreign body sensation with pegfilgrastim and for blood is sputum, allergy to 
Neulasta and foreign body sensation with bevacizumab and doxorubicin hydrochloride.
The company assessed the causality for blood is sputum and foreign body sensation with pegfilgrastim as 
Print Time: 15-JUL-2016 02:35 PM If a field is blank, there is no data for that field Page 33 of 517
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
unrelated and for blood is sputum, allergy to Neulasta and foreign body sensation with bevacizumab and 
doxorubicin hydrochloride as unrelated.
No further information was provided.
Additonal information was received on 22/Jan/2007. Following information was added to case. Bevacizumab 
therapy details: indication, frequency and start date were added.